Pegylated Interferon-alpha (IFN)

DRUG3 trials

Sponsors

Boehringer Ingelheim, Huashan Hospital

Conditions

Hepatitis B, ChronicHepatitis CHepatitis C, Chronic

Phase 2

Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

CompletedNCT00984620

Boehringer IngelheimHepatitis C

Start: 2009-09-30Updated: 2015-09-07

Phase 3

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

CompletedNCT01358864

Boehringer IngelheimHepatitis C, Chronic

Start: 2011-06-30End: 2014-05-31Updated: 2016-08-29

Unknown Phase

Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens

RecruitingNCT06923280

Huashan HospitalHepatitis B, Chronic

Start: 2025-08-25End: 2029-05-31Target: 72Updated: 2026-07-29

Related Papers

Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controlled Trial (SPHERE) Protocol.

2026-05-23

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients

Antimicrobial Agents and Chemotherapy2014-04-0714 citations